https://transhumanist.ru/index.php?action=history&feed=atom&title=SLCO1B1SLCO1B1 - История изменений2026-04-25T11:06:30ZИстория изменений этой страницы в викиMediaWiki 1.43.6https://transhumanist.ru/index.php?title=SLCO1B1&diff=4370&oldid=prevOdysseusBot: Новая страница: «Solute carrier organic anion transporter family member 1B1 (Liver-specific organic anion transporter 1) (LST-1) (OATP-C) (Sodium-independent organic anion-transpo...»2021-04-29T19:14:40Z<p>Новая страница: «Solute carrier organic anion transporter family member 1B1 (Liver-specific organic anion transporter 1) (LST-1) (OATP-C) (Sodium-independent organic anion-transpo...»</p>
<p><b>Новая страница</b></p><div>Solute carrier organic anion transporter family member 1B1 (Liver-specific organic anion transporter 1) (LST-1) (OATP-C) (Sodium-independent organic anion-transporting polypeptide 2) (OATP-2) (Solute carrier family 21 member 6) [LST1] [OATP1B1] [OATP2] [OATPC] [SLC21A6]<br />
<br />
==Publications==<br />
<br />
{{medline-entry<br />
|title=The [[SLCO1B1]] c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.<br />
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/24263182<br />
|abstract=The [[SLCO1B1]] c.521T>C polymorphism is associated with statin plasma levels and simvastatin-induced adverse drug reactions. We studied whether the c.521T>C polymorphism is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy, because these events are indicators of adverse drug reactions. We identified 1939 incident simvastatin and atorvastatin users in the Rotterdam Study, a population-based cohort study. Associations were studied using Cox proportional hazards analysis. Meta-analysis was performed with data from the Utrecht Cardiovascular Pharmacogenetics study. Simvastatin users with the c.521 CC genotype had a significantly higher risk of a dose decrease or switch than users with the TT genotype [hazard ratio (HR) 1.74, 95% confidence interval (CI) 1.05-2.88]. Female sex, age below 70 years, and low starting dose were risk factors. In atorvastatin users with starting dose of more than 20 mg, the risk of a dose decrease or switch was higher in users carrying a C allele than in users with the TT genotype (HR 3.26, 95% CI 1.47-7.25). In the meta-analysis the association in simvastatin users remained, with a significantly higher risk of a dose decrease or switch in simvastatin users with two minor alleles (HR 1.69, 95% CI 1.05-2.73). For atorvastatin users no significant association was found. In simvastatin users in the Rotterdam Study, we demonstrated an association between the c.521T>C polymorphism and dose decrease or switching, as indicators of adverse drug reactions, and provided risk factors for this association. For atorvastatin, an association was found in users with a starting dose of more than 20 mg.<br />
|mesh-terms=* Aged<br />
* Aging<br />
* Anticholesteremic Agents<br />
* Atorvastatin<br />
* Cholesterol<br />
* Cytosine<br />
* Databases, Factual<br />
* Dose-Response Relationship, Drug<br />
* Female<br />
* Genetic Association Studies<br />
* Heptanoic Acids<br />
* Humans<br />
* Hypercholesterolemia<br />
* Liver-Specific Organic Anion Transporter 1<br />
* Male<br />
* Middle Aged<br />
* Organic Anion Transporters<br />
* Polymorphism, Single Nucleotide<br />
* Prospective Studies<br />
* Pyrroles<br />
* Risk Factors<br />
* Sex Characteristics<br />
* Simvastatin<br />
* Thymine<br />
<br />
|full-text-url=https://sci-hub.do/10.1097/FPC.0000000000000018<br />
}}</div>OdysseusBot